Clinical Trials - KYTX

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06588491KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD-19 CAR T) Therapy, in Subject With Treatment Refractory Stiff Person SyndromeRECRUITINGPHASE22024-09-252026-122026-04
NCT06384976KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisACTIVE_NOT_RECRUITINGPHASE22024-09-202029-012027-04
NCT06193889KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisRECRUITINGPHASE2, PHASE32024-08-282028-092027-09
NCT06400303KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic SclerosisACTIVE_NOT_RECRUITINGPHASE1, PHASE22024-08-062027-032026-03
NCT05938725KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisRECRUITINGPHASE1, PHASE22023-04-282026-082025-08
NCT06342960KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisRECRUITINGPHASE1, PHASE22022-12-012029-012028-10